Abstract:Nicotinic acetylcholine receptors (nAChRs) of the cerebral cortex and cerebellum of rats were evaluated by a radioligand binding assay, employing tissue segments, or homogenates as materials. [3H]-epibatidine specifically bound to nAChRs in rat cortex or cerebellum, but the dissociation constants for [3H]-epibatidine differed between segments and homogenates (187 pM for segments and 42 pM for homogenates in the cortex and 160 pM for segments and 84 pM for homogenates in the cerebellum). The abundance of total … Show more
“…In particular, the decrease in binding was greater for [ 3 H]‐NMS‐binding (more than 10% reduction) than for [ 3 H]‐CGP‐12,177‐binding sites (20–50% reduction) in the three regions. This preliminary result implies that many airway samples should be pooled in the case of homogenate binding, and that homogenization causes a large loss in yield of airway tissue receptors, similar to other tissues and radioligands (Tanaka et al., 2004; Wang et al., 2011).…”
Section: Resultsmentioning
confidence: 93%
“…Regardless of the presence or absence of cartilage, the airway segments were directly incubated with radioligands in physiological solution. As epithelial and muscle layers were not scraped from the cartilage, and in contrast to a marked reduction of [ 3 H]‐NMS and [ 3 H]‐CGP‐12,177 binding in homogenates (Figure 2), the present segment binding assay is less prone to loss of receptors and to modification of the natural environment/conformation of the receptors (Wang et al., 2011). However, the airway segments used in the present study were heterogeneous tissues that included various types of cells, as shown in Figure 1.…”
BACKGROUND AND PURPOSEMuscarinic acetylcholine receptors (mAChRs) and b-adrenoceptors in the airways and lungs are clinically important in chronic obstructive pulmonary disease (COPD) and asthma. However, the quantitative and qualitative estimation of these receptors by radioligand binding approaches in human airways has not yet been reported because of tissue limitations.
EXPERIMENTAL APPROACHThe regional distribution and relative proportion of mAChR and b-adrenoceptor subtypes were evaluated in human bronchus and lung parenchyma by a tissue segment binding method with [
KEY RESULTSThe M3 subtype predominantly occurred in the bronchus, but the density decreased from the segmental to subsegmental bronchus, and was absent in lung parenchyma. On the other hand, the M1 subtype occurred in the lung only, and the M2 subtype was distributed ubiquitously in the bronchus and lungs. b2-adrenoceptors were increased along the airways, and their densities in the subsegmental bronchus and lung parenchyma were approximately twofold higher than those of mAChRs in the same region. b1-adrenoceptors were also detected in lung parenchyma but not in the bronchus. The muscarinic contractions and adrenoceptor relaxations in both bronchial regions were mediated through M3-mAChRs and b2-adrenoceptors, respectively.
CONCLUSIONS AND IMPLICATIONSFrom the present radioligand binding approach with intact tissue segments, we constructed a distribution map of mAChRs and b-adrenoceptors in human bronchus and lung parenchyma for the first time, providing important evidence for future pharmacotherapy and new drug development for respiratory disorders.
“…In particular, the decrease in binding was greater for [ 3 H]‐NMS‐binding (more than 10% reduction) than for [ 3 H]‐CGP‐12,177‐binding sites (20–50% reduction) in the three regions. This preliminary result implies that many airway samples should be pooled in the case of homogenate binding, and that homogenization causes a large loss in yield of airway tissue receptors, similar to other tissues and radioligands (Tanaka et al., 2004; Wang et al., 2011).…”
Section: Resultsmentioning
confidence: 93%
“…Regardless of the presence or absence of cartilage, the airway segments were directly incubated with radioligands in physiological solution. As epithelial and muscle layers were not scraped from the cartilage, and in contrast to a marked reduction of [ 3 H]‐NMS and [ 3 H]‐CGP‐12,177 binding in homogenates (Figure 2), the present segment binding assay is less prone to loss of receptors and to modification of the natural environment/conformation of the receptors (Wang et al., 2011). However, the airway segments used in the present study were heterogeneous tissues that included various types of cells, as shown in Figure 1.…”
BACKGROUND AND PURPOSEMuscarinic acetylcholine receptors (mAChRs) and b-adrenoceptors in the airways and lungs are clinically important in chronic obstructive pulmonary disease (COPD) and asthma. However, the quantitative and qualitative estimation of these receptors by radioligand binding approaches in human airways has not yet been reported because of tissue limitations.
EXPERIMENTAL APPROACHThe regional distribution and relative proportion of mAChR and b-adrenoceptor subtypes were evaluated in human bronchus and lung parenchyma by a tissue segment binding method with [
KEY RESULTSThe M3 subtype predominantly occurred in the bronchus, but the density decreased from the segmental to subsegmental bronchus, and was absent in lung parenchyma. On the other hand, the M1 subtype occurred in the lung only, and the M2 subtype was distributed ubiquitously in the bronchus and lungs. b2-adrenoceptors were increased along the airways, and their densities in the subsegmental bronchus and lung parenchyma were approximately twofold higher than those of mAChRs in the same region. b1-adrenoceptors were also detected in lung parenchyma but not in the bronchus. The muscarinic contractions and adrenoceptor relaxations in both bronchial regions were mediated through M3-mAChRs and b2-adrenoceptors, respectively.
CONCLUSIONS AND IMPLICATIONSFrom the present radioligand binding approach with intact tissue segments, we constructed a distribution map of mAChRs and b-adrenoceptors in human bronchus and lung parenchyma for the first time, providing important evidence for future pharmacotherapy and new drug development for respiratory disorders.
“…The 6 mL of filter count scintillation cocktail (Perkin-Elmer Life Science, Boston, MA) was added to each vial and radioactivity was counted by Tri-Carb Liquid Scintillation Counter (Perkin-Elmer Life Science, Boston, MA). The 10G 5 M concentration of nicotine bitartrate was used for non-specific binding 20 . Muscarinic and nicotinic receptor binding inhibition data were presented as B/B 0 (%) (transformed from the cpm counts of the tested compounds) and means of logarithmic concentrations±standard error of the mean of four to six experiments conducted in duplicate.…”
Background and Objective: Hypericum perforatum L. (HP) is a popular herbal medicine with different pharmacological effects. This study investigated the possible cholinergic receptor affinities of HP extract and its three active constituents: hyperforin, hypericin and pseudohypericin. Materials and Methods: Radioactive compounds [3H]-N-methyl scopolamine used for muscarinic receptor binding studies in Chinese hamster ovary cells expressing human muscarinic receptor subtypes and [3H]-cytisine used for nicotinic receptor binding tests performed with mouse brains without a cerebellum. Muscarinic binding inhibition was observed with HP extract considerably for hM2 and hM5. Results: Hyperforin, hypericin and pseudohypericin showed a much lower affinity for muscarinic receptors at higher concentrations. The HP extract and its constituents did not produce any nicotinic receptor binding inhibition. Conclusion: These results suggested that post-junctional direct muscarinic receptor interaction may modulate some effects of HP extract and its constituents however different mechanisms apart from direct cholinergic receptor interaction might be considered for the pharmacological actions of hyperforin, hypericin and pseudohypericin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.